Timing of new black box warnings and withdrawals for prescription medications

JAMA

Volumn 287, Issue 17, 2002, Pages 2215-2220

  Lasser, Karen E ^a   Allen, Paul D ^a   Woolhandler, Steffie J ^a   Himmelstein, David U ^a   Wolfe, Sidney M ^b   Bor, David H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Public Citizen Health Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; ATENOLOL; CAPTOPRIL; CARMUSTINE; CISAPRIDE; CLOZAPINE; CYCLOSPORIN; DACARBAZINE; DANAZOL; DISOPYRAMIDE; ENALAPRIL MALEATE; ENCAINIDE; FLECAINIDE ACETATE; GANCICLOVIR; ISOTRETINOIN; KETOCONAZOLE; LISINOPRIL; LOMUSTINE; METOPROLOL; MEXILETINE; MIDAZOLAM; MITOXANTRONE; NEW DRUG; PEMOLINE; PROPAFENONE; RIBAVIRIN; TOCAINIDE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

ARTICLE; BONE MARROW TOXICITY; BRAIN PSEUDOTUMOR; CARDIOTOXICITY; DRUG APPROVAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; LACTIC ACIDOSIS; LIVER TOXICITY; LUNG FIBROSIS; PELIOSIS HEPATIS; PRIORITY JOURNAL; PROBABILITY; RASH; RESPIRATION DEPRESSION; SPINAL CORD HEMORRHAGE; STROKE; THROMBOSIS;

EID: 0036570099     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.17.2215     Document Type: Article

References (60)

1. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
2. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs
3. How should efficacy be evaluated in randomized clinical trials of treatments for depression?
4. Thrombotic thrombocytopenic purpura and clopidogrel: A need for new approaches to drug safety
5. The safety of new medicines: The importance of asking the right questions
6. How a new policy led to seven deadly drugs
7. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety
8. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective
9. Proposed rules
10. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: Looking back and looking ahead
11. Modernizing the FDA: An incremental revolution
12. Black box warnings in prescription drug labeling: Results of a survey of 206 drugs
13. The Physicians' Desk Reference: Problems and possible improvements
14. Incorrect overdose management advice in the Physicians' Desk Reference
15. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference
16. How should efficacy be evaluated in randomized clinical trials of treatments for depression?
17. Safety of FDA-approved drugs
18. The role of commercial sources in the adoption of a new drug
19. Information sources and clinical decisions
20. Prescribing new drugs: Qualitative study of influences on consultants and general practitioners
21. The impact of a direct-to-consumer prescription medication advertising campaign on new prescription volume
22. Pushing pills with piles of money: Merck and Pharmacia in arthritis drug battle
23. Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals
24. The synergic impact of promotion intensity and therapeutic novelty on market performance of prescription drug products